Medmix Ag · SIX:MEDX
Medmix — Investor Day (May 2022)
48 slides from Medmix's investor day presentation, May 20, 2022
Slide 1: medmix Analyst Day
Slide 2: The safe harbor statement under the US private securities litigation reform act 1995
The safe harbor statement under the US private securities litigation reform act 1995 This presentation may contain forward-looking statements, including but not limited to, projections of financial developments, market activities or future performance of products and solutions, containing risks and
Slide 3: Welcome
%§ medmix Welcome
Slide 4: Agenda
Agenda 10:30 Introduction and deep-dives in Healthcare segments Introduction – Girts Cimermans (CEO) Dental – Holger Arens (Head Dental) Drug Delivery – Dominik Vonier (Head Drug Delivery) Surgery – Ayse Sanlioglu (Head Surgery) 12:30 Lunch 13:30 Factory tour 14:30 Q&A 15:00 Bus leaves to Zurich
Slide 5: Introduction
Introduction Girts Cimermans, CEO
Slide 6: medmix overview
medmix overview Global footprint 1,900 12 production sites employees CHF ~450m >2.5bn revenue (expected 2021) 8 Products per year ~900 active patents brands
Slide 7: Innovative, high-precision delivery devices serving attractive markets
Innovative, high-precision delivery devices serving attractive markets Healthcare Consumer and Industrial Drug Dental Surgery Industry Beauty Delivery Gold standard in Award winning, Pioneer in bone Leader in industrial mixing Leading microbrush dental mixing device proprietary injection cement mixi
Slide 8: Attractive fundamental macro trends
Attractive fundamental macro trends Market growth forecast post Macro trends recovery to 2025E (CAGR)1,2 Main segment trends • Emerging markets shift away from hand- to device-mixing Growing Dental middle-class market 4% • Trend to unit-dose to avoid cross-contamination • Growing number of dentists
Slide 9: Growth initiatives overview
Growth initiatives overview Lean, innovative and customer centric Ready for growth ...with specific initiatives and targets Further grow in Healthcare 20+ organic initiatives and active M&A pipeline Become a local player in China Acquisition opportunities identified for Beauty and Industry Attractiv
Slide 10: Organic medium-term growth ambition – 8% CAGR
Organic medium-term growth ambition – 8% CAGR Organic growth rates – mid-term ambition Today’s focus ▪ Growth in Healthcare driven by Drug Delivery ▪ Drug Delivery ambition to reach CHF100m revenue mid- term from 40.8m in 2021 CAGR Approaching ▪ Dental and Surgery expected to outpace market growth C
Slide 11: M&A offers additional growth potential
M&A offers additional growth potential Clear focus – disciplined approach M&A focus – Healthcare M&A focus – China Niche ▪ Small to mid-sized companies in adjacencies leader ▪ Shanghai production facility focusing on export and international OEMs distributing in China − Strong own IP ▪ Need to be pr
Slide 12: New sustainable products
New sustainable products Beauty expands its range of Industry celebrates MIXPAC’s Drug Delivery start to use sustainable devices 1st 100% PCR PP cartridge renewable source, bio-based plastic with 84 % less CO2 per kg ≈ 36% • new liquid concealer system • 100% post-consumer recycled (PCR) poly- • Usa
Slide 13: Sustainability
Sustainability Planet, People and Profit Our approach is based on meaningful actions that support our areas of focus. Here are some highlights from 2021 Planet • We took actions to reduce emissions and switch our sites to low carbon electricity. 8 out of 13 sites now operate on low carbon electricit
Slide 14: Dental
Dental wn Cc ov a <x u J) DD {e) x
Slide 15: PEG: our plan to win
ASPIRATION To become the leading dental application delivery provider by 2026. Protect PEG is our plan to win P The core business E G Into adjacent market Grow our currently served segments with new market segments with products and value-added new products and value- solutions added solutions Expan
Slide 16: Dental – Business snapshot
Dental – Business snapshot Segment overview Key revenue split (Q1 2022) ▪ Provider of application solutions, mixers, needles, By customer type By application syringes and filling solutions for the dental Dental Aesthetics Anaesthetics consumable industry distribution 2% 2% 8% ▪ Our mixers are a glob
Slide 17: Dental – Strategic priorities and initiatives
DENTAL – Strategic priorities and initiatives Further room to grow in under-represented sub-segments Market size 2020: ~CHF350m – Market growth forecast (CAGR 21E-25E): 4.0% – Market share of medmix 2020: ~20% PROSTHETICS RESTORATIVES ANESTHETICS ENDODONTICS ESTHETICS Market share <60% <15% <5% <5%
Slide 18: Prosthetics
PROSTHETICS Impression Bite Registration Temp. Materials Why customers buy… • MIXPAC = THE GOLD STANDARD • Comprehensive MIXPAC application “Eco” System • Consistently fast & optimum mixing quality for clinical long-term results vs. manual mixing
Slide 19: MIXPAC T-Mixer
MIXPAC™ T-Mixer™ Award winning product and outstanding quality
Slide 20: Prosthetics – Cementation
PROSTHETICS Cementation Why customers buy… • Expertise in fluid handling, dispensing & application • IP protected solutions • Customized product solutions with outstanding quality
Slide 21: Restoratives
RESTORATIVES P E G Adhesives & Composites Grow Why customers buy… • Reliable co-creation partner for our customers • High degree of individualization (plunger/color/ grip plate)
Slide 22: Esthetics
ESTHETICS P E G Grow Why customers buy… • medmix = full-service solutions provider from product design until fulfilment • Innovative solutions to create added value for differentiation in a highly commoditized market
Slide 23: Full-service solutions
FULL-SERVICE SOLUTIONS Why customers buy… • Limited expertise of OEMs in primary packaging and filling (focus on material development) • Increasing regulatory requirements • Global logistics and distribution challenges ➢ medmix = full-service solutions provider from R&D to fulfilment
Slide 24: Dental – Strategic priorities and initiatives
Dental – Strategic priorities and initiatives Focus on product expansion and new regions Strategic growth vectors Strategic priorities Product expansion 1 Develop new products for adjacent applications Customer development 2 Expand coverage and increase customer base in China, India and Brazil New c
Slide 25: Drug Delivery
Drug Delivery Dominik Vonier
Slide 26: Sales snapshot today vs large market opportunity
Sales snapshot today vs large market opportunity Drug Delivery Today Injection Devices Market Opportunity (with example indications) Sales Split Number of devices in 2025e Diabetes 20 Growth hormones Fertility 150 Osteoporosis 300 Non-insulin diabetes / GLP-1 / obesity Auto-immune Oncology Biologics
Slide 27: Pen market strong growth driven by long term trends
Pen market strong growth driven by long term trends Pen injector market (excluding diabetes captive) (CHFm) Long term supportive macro trends CAGR 21E-25E • Diabetes type 2 growth due to obesity 1’301 (%) 1’218 1’135 • Aging population 1’059 987 916 526 573 Diabetes1 8 • Self-injection at home to re
Slide 28: Biologics' strong growth driving rise of injectables
Biologics’ strong growth driving rise of injectables Routes of administration (global marketed 2020, USD trillions)1 Global injectables growth by container (USD, 2020)1 +5% CAGR ’15-20 1.1 10% 2% 0.9 Other 11% 45% 9% Injectables 37% Oral 52% 46% 2%% 2015 2020 ~60% of global drug pipeline are Autoinj
Slide 29: Several platforms covering most relevant market needs
Several platforms covering most relevant market needs Disposable Re-Usable Autoinjectors Pen Injectors Pen Injectors D-Flex™ Re-Vario™-A PiccoJect™ Axis-D™ Re-Vario™ Pentek™
Slide 30: D-Flex Platform
D-Flex™ Platform Faster Execution One pen, several indications The versatile solution Safe to use for patients Disposable pen for only one or multi Allows manual, multiple Patients cannot set distinguish fixed dosages injections with a single pen unintended dosage Low investment cost Perfect for cli
Slide 31: PiccoJect – Autoinjector Platform
PiccoJect™ – Autoinjector Platform High performance in small device Commitment to sustainability Intuitive and easy to use Support for 1 ml long and 2.25 ml PFS Design and manufacturing focused Standard two step operation in a device that is smaller than on reducing carbon intensity with enhanced us
Slide 32: Digital: Connected Cap and Logbook
Digital: Connected Cap and Logbook The smart way to control patient adherence in clinical trials Based on a proven technology successful clinical trial with 75 diabetes patients1) Automatic injection data collection expelled dose, time and temperature Identical injection process no additional patien
Slide 33: Drug delivery 2025 revenue target: CHF 100 million
Drug delivery 2025 revenue target: Chf 100 million 80% of target covered with signed projects or products on market Expected revenue development Secured new products by API clinical stage CHF 100m Expected 2025 revenue split by indication Secured: US biotech at 100% plan, other secured at 75% plan P
Slide 34: Surgery
Surgery 2 D 2 c © ea) wv Va) > <x
Slide 35: Surgery – Market overview (1/2)
Surgery – Market overview (1/2) Selected products Focused applications Prefilled Ergosyringe double syringe system Bone Repair Bone putty delivery system – minimally invasive Liquid/powder mixing Bone cement Tissue Repair and delivery device delivery syringe
Slide 36: Bone Repair Applications
Bone Repair Applications Spine Spine Applications MISS Medmix Solution Surgeons Pain Points Medmix Value Proposition • Challenging access • Large portfolio w various size options • Different biomaterials with different prep • Strong knowhow on biomaterials times • Ready to deliver, all in one soluti
Slide 37: Tissue Repair Applications
Tissue Repair Applications Cardiovascular Repair CV Applications CABG Medmix Solution • Coronary Bypass Artery Surgery • Heart Transplant • Heart Revascularization • Heart Valve Surgery • Aneurysm Repair • Pacemaker Surgery Surgeons Pain Points Medmix Value Proposition • Patients with multiple risk
Slide 38: Tissue Banks
Tissue Banks • Tissue Banks process donated human tissue for use in medical procedures • Allograft is bone harvested from a cadaver donor, are used in a number of procedures to save lives, repair limbs, relieve pain, or improve a patient's quality of life. orthopedics, neurosurgery, dental surgery,
Slide 39: Tissue Banks – Allograft Journey
Tissue Banks Allograft Journey Pre-Procurement Procurement Preparation After Processing Commercialization • Notification of • Acceptance of • Soft tissue stripping • Visual prospective donor’s donor tissue • Initial size reduction inspection test death • Donor screening & • Cleaning & • Residual • C
Slide 40: Market Trends
Market Trends Attractive Market with Few Players & High Barriers for Entry Market Trends Implications for Medmix Patients • Increasing obesity & diabetes cause surgical • Increasing number of biomaterials that needs challenges and increase rate of complications – applicator systems difficult access
Slide 41: Surgery – Market Overview
Surgery – Market Overview Selected customers • Global OEMs : Stryker, Zimmer, Baxter, Artherex, JnJ • Mid Size Players: AMS, Joline, • Incubators: Tulavi, Bioventus, Abyrx, Tetec • Tissue Banks: DCI, Community Tissue Services, Viant SA • Service Providers: Instant Systems, LifeNet Health Selected co
Slide 42: Medmix Product Journey
Medmix Product Journey Biologics Company SURGEON • Co-creation • Design • Manufacture • Filling • Submission for Certification as final • Assemble • Sterilization product (FDA,CE) • Additional value added • Packaging • Commercialization services (sterilization) • Pre-clinical • Distribution evaluati
Slide 43: Surgery – Market outlook
Surgery – Market outlook Surgery Applicator System Market market1 How we grow into new markets (CHFm) CAGR 21E-25E replacement (%) Joint 217 7.52 Product development 203 190 Bone repair 43 5.0 178 (joint replacement) 42 171 162 42 40 treatment 35 147 35 Tissue % 130 growth vs PY 29 *exc. Cryolife me
Slide 44: Surgery – Business snapshot
Surgery – Business snapshot Segment overview Business Overview Key revenue split (FY 21) ▪ Established with acquisition of Medmix Systems in 2018, nearly doubled sales since acquisition By customer group By region ▪ A leading provider of highly specialized surgical delivery devices for biomaterials
Slide 45: Additional growth opportunities
Additional growth opportunities Focus on growing new business and expanding current footprint Strategic growth vectors Strategic priorities 1 Offer tailor-made devices to large OEMs (key differentiator) Grow customer base 2 Expand portfolio with devices for joint replacement & aesthetics Product Dev
Slide 46: Why choose Medmix?
Why choose Medmix? • Well known Medmix brand with 15 years of experience on biomaterial mixing, containment and delivery • Deliver value thru design • Strong track record on quality and innovation • Expertise on regulatory environment • Extensive IP portfolio • Sales and marketing team with strong u
Slide 47: medmix
4 medmix
Slide 48: Your Investor Relations contact
Your Investor Relations contact Christoph Ladner Sheel Gill Head IR Sulzer Head M&A, Strategy and IR Phone: +41 52 262 30 22 +41 41 723 73 57 Mobile: +41 79 326 69 70 E-mail: investorrelations@medmix.com sheel.gill@medmix.com medmix AG Neuhofstrasse 20 6340 Baar Switzerland